Corcept Stock Plunges 50% After FDA Rejects Relacorilant Application

Corcept Therapeutics shares plunged 50.50% to $34.74 (down $35.45) after the FDA issued a Complete Response Letter for relacorilant, leaving the drug unapproved and outlining additional requirements; the stock had closed at $70.19, opened near $70, and traded intraday between $33.80 and about $71.25. The regulatory setback creates material uncertainty around relacorilant's commercial prospects, drove trading volume well above average, and exacerbates valuation risk for a company already showing wide 52-week volatility (~$39.50–$103.25).

Analysis

Market structure: The CRL sharply re-rates CORT (now trading ~ $35 from ~$70), creating immediate winners: buyers of protection (puts, tail hedges) and larger pharma groups that could acquire the program at distressed prices; losers are existing CORT long holders, small-cap biotech beta funds, and any suppliers tied to milestone payments. Pricing power shifts away from Corcept for relacorilant—market now prices a low-probability (>20%) near-term approval and meaningful dilution or asset-sale scenarios over 6–18 months. Cross-asset: expect a +200–400% surge in CORT option IVs over 1–5 trading days, modest widening of CORT credit spreads, negligible FX/commodity impact, and potential negative flow into XBI/IBB on biotech sentiment offload.

Risk assessment: Tail risks include a) full program termination or license loss triggering >90% downside; b) rapid dilutive financing at equity prices <$40 within 30–90 days; c) management/board turnover igniting litigation. Immediate (days) risks are volatility and liquidity squeezes; short-term (weeks–months) are dilution and secondary offerings; long-term (quarters–years) hinge on FDA re-submission timeline (likely 6–18 months) and new phase 3/analytical work. Hidden dependencies: cash runway, milestone obligations, and potential buyout offers tied to contingent liabilities — any one can materially change equity value.

Trade implications: Direct: initiate a tactical short of CORT (target size 2–4% portfolio) or buy a 90-day bear put spread to limit premium (buy $30 / sell $20 puts) to capitalize on IV and downside to $20–25 if dilution occurs. Pair trade: short CORT / long XBI equal-dollar (or IBB) to neutralize sector beta; allocate 1–2% net. Options: consider buying 6–9 month out-of-the-money puts if seeking asymmetric payoff vs immediate resale dilution; avoid naked short uncovered due to squeeze risk. Rotate 2–5% from small-cap biotech into large-cap defensive pharma (PFE, MRK) over next 2–6 weeks.

Contrarian: The market likely overstates binary FDA risk in the medium term—CRLs are often addressable with additional analyses and targeted studies; historical CRL recoveries show 6–12 month refile windows that can re-rate stock +50–200% if credible plan announced. Mispricings: post-CRL IV is bloated—selling nearer-term volatility via bear-call spreads can be lucrative if no immediate re-filing occurs. Unintended consequence of heavy shorting: a well-structured partnership or acquisition offer at $40–60 could produce sharp squeezes; size shorts conservatively and use tight stops at $50 within 2–4 weeks if liquidity returns.

Key Decisions for Investors

• Establish a 3% portfolio short position in CORT (ticker: CORT) using equity or borrow; target add zone $40–50 if recovery rally; hard stop loss at $60 and size to cap max loss at 1.5% portfolio.
• Buy a 90-day bear put spread on CORT: buy $30 strike / sell $20 strike (1–2% portfolio notional) to capture downside to $20 with defined max loss; if priced expensively, shift to 120-day calendar for lower weekly theta.
• Implement pair trade: short CORT equal-dollar and long IBB (or XBI) for 1–2% net exposure to isolate company-specific risk; rebalance in 2–6 weeks based on FDA communications.
• Reduce small-cap biotech exposure by 2–4% and reallocate into large-cap defensive pharma (PFE, MRK) over next 7–21 days to hedge sector volatility and credit spread widening.
• Monitor three triggers over the next 30–90 days before adding long: FDA minutes/CRL detail release, company cash runway disclosure (months of runway <12 should force fresh downside), or a credible refile/timeline announcement — only add long if timelines <12 months and dilution risk quantified.